drugset / Trial / NCT03781986
APG-115 in Salivary Gland Cancer Trial
Phase 1/2
Active not recruiting
41 enrolled
University of Michigan Rogel Cancer Center
Ascentage Pharma Group Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase I/II trial to evaluate the efficacy of APG-115 +/- Carboplatin for the treatment p53 wild-type malignant salivary gland cancer. Part 1 consisted of 2 arms, arm A (APG-115 monotherapy) and arm B (APG-115 + Carboplatin) and was terminated early. Part 2 is a single arm study (APG-115 monotherapy).
Timeline
- Start
- 2019-10-28
- Primary completion
- 2026-01-19
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alrizomadlin | Small molecule | 150 mg | Oral |
| Subject | Carboplatin | Small molecule | 4.5 unknown | Intravenous |